Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective: To synthesise evidence from exclusively primary prevention data on the effectiveness of statins for prevention of cardiovascular disease (CVD), including stroke, and outcomes stratified by baseline risk and gender. Design: Overview of systematic reviews (SRs) using Revised-AMSTAR approach to assess quality. Data sources: Cochrane Database of Systematic Reviews, MEDLINE, Embase, PubMed, Scopus and PROSPERO to June 2017. Eligibility criteria for selecting studies: SRs of randomised control trials (RCTs) or individual patient data (IPD) from RCTs, examining the effectiveness of statins versus placebo or no treatment on all-cause mortality, coronary heart disease, CVD (including stroke) and composite endpoints, with stratification by baseline risk and gender. Data extraction and synthesis: Two independent reviewers extracted data and assessed methodological quality. A narrative synthesis was conducted. Results: Three SRs were included. Quality of included SRs was mixed, and none reported on the risk of bias of included trials. We found trends towards reduced all-cause mortality in all SRs (RR 0.91 [95% CI 0.85 to 0.97]), (RR 0.91 [95% CI 0.83 to 1.01]) and (RR 0.78 [95% CI 0.53 to 1.15]) though it was not statistically significant in two SRs. When stratified by baseline risk, the effect on all-cause mortality was no longer statistically significant except in one medium risk category. One review reported significant reductions (RR 0.85 [95% CI 0.77 to 0.95]) in vascular deaths and non-significant reductions in non-vascular deaths (RR 0.97 [95% CI 0.88 to 1.07]). There were significant reductions in composite outcomes overall, but mixed results were reported in these when stratified by baseline risk. These reviews included studies with participants considered risk equivalent to those with established CVD. Conclusions: There is limited evidence on the effectiveness of statins for primary prevention with mixed findings from studies including participants with widely ranging baseline risks. Decision making for the use of statins should consider individual baseline risk, absolute risk reduction and whether risk reduction justifies potential harms and taking a daily medicine for life. Trial registration number: CRD42017064761.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934 · cited 1×
“Statins, or 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors, are a class of lipid-lowering drugs and are first choice agents for reducing plasma LDL cholesterol and thereby reducing CVD risk.(2) Statins may be used for the primary or secondary prevention of CVD.”
BackgroundInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“8 However, there is ongoing debate about these changes, 9–11 as they have tended to expand the number of people eligible for treatment, particularly in primary prevention.”
BackgroundHow to Use a Subgroup Analysis: Users’ Guide to the Medical Literature
Sun, X., Ioannidis, J. P. A., Agoritsas, T., Alba, A. C., & Guyatt, G. (2014) · JAMA · doi:10.1001/jama.2013.285063 · Cited by 550 · cited 1×
“However, this overview clearly elucidates the information that is available at present allowing patients and clinicians to know that this is the best, although limited, data available.”
BackgroundMurad, M. H., Montori, V. M., Ioannidis, J. P. A., Jaeschke, R., Devereaux, P. J., Prasad, K., Neumann, I., Carrasco-Labra, A., Agoritsas, T., Hatala, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.5559 · Cited by 454
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · cited 3×
“The reviews by Mora et al and Ray et al were assigned ratings of 19 and 32, respectively, out of a maximum score of 44 (see table 4).”
BackgroundInfluentialPrimary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333
Kung, J. (2010) · The Open Dentistry Journal · doi:10.2174/1874210601004020084 · Cited by 329 · cited 1×
“28 One of the included SRs, published by the Cholesterol Treatment Trialists’ Collaboration (CTT), consisted of analyses of IPD and was reported in two publications based on the same trials, one reporting results overall 29 and one that included analyses stratified by gender.”
ResultPage, M. J., McKenzie, J. E., Kirkham, J., Dwan, K., Kramer, S., Green, S., & Forbes, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000035.pub2 · Cited by 281
Should people at low risk of cardiovascular disease take a statin?
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013) · BMJ · doi:10.1136/bmj.f6123 · Cited by 208 · cited 2×
“41 Inclusion of this trial could have influenced the results reported in the included reviews in those in the intermediate risk category.”
BackgroundResultBias Due to Changes in Specified Outcomes during the Systematic Review Process
Kirkham, J. J., Altman, D. G., & Williamson, P. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009810 · Cited by 164 · cited 1×
“36 Mora et al analysed the components of the composite outcome total CVD events in women in one large trial included in their review and found that women had a significant reduction in revascularisations and unstable angina but not in other components of the composite outcome, including stroke.”
BackgroundPetretta, M., Costanzo, P., Perrone-Filardi, P., & Chiariello, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.001 · Cited by 141
Cited by
Bougioukas, K. I., Vounzoulaki, E., Mantsiou, C. D., Savvides, E. D., Karakosta, C., Diakonidis, T., Tsapas, A., & Haidich, A.-B. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.12.004 · Cited by 117
“study [28]), every set is shown with circles, but as soon as we get to four SRs, circles do not work (Table 1).”
BackgroundEffect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac615 · Cited by 116
Byrne, P., Demasi, M., Jones, M., Smith, S. M., O’Brien, K. K., & DuBroff, R. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0134 · Cited by 114
Self-citationStatins for primary prevention of cardiovascular disease
Byrne, P., Cullinan, J., & Smith, S. M. (2019) · BMJ · doi:10.1136/bmj.l5674 · Cited by 53
Self-citation
Metadata
- Authors
- Byrne, P., Cullinan, J., Smith, A., & Smith, S. M.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-04
- Volume
- 9
- Issue
- 4
- Pages
- e023085
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2942264817
- Cited by
- 75
- References
- 22
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.